Samphire Neuroscience Ltd

Samphire Neuroscience Ltd specialises in neurostimulation devices, such as the Nettle system. These devices are designed to address pain and mood symptoms linked to hormonal changes, focusing on non-invasive or minimally invasive brain modulation for symptom management.

Samphire Neuroscience Ltd is headquartered in the United Kingdom. The company’s location is relevant for regulatory compliance and device registration purposes, particularly within the EU.

Samphire Neuroscience Ltd’s devices are registered in the EUDAMED database, which is the European Union’s centralised system for tracking medical devices and their manufacturers. This registry is used for transparency and compliance with EU regulations.

Samphire Neuroscience Ltd’s devices fall under EU Class IIa classification. This classification is determined based on the risk associated with the device’s intended use, with Class IIa indicating moderate risk requiring specific conformity assessment procedures before market placement.